Insider Trading Alert - ENTA, KMG And AMAG Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 8, 2015, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $600.00 to $33,225,000.00.

Highlighted Stocks Traded by Insiders:

Enanta Pharmaceuticals (ENTA) - FREE Research Report

Or Yat Sun, who is Chief Scientific Officer at Enanta Pharmaceuticals, sold 10,750 shares at $42.02 on June 8, 2015. Following this transaction, the Chief Scientific Officer owned 219,481 shares meaning that the stake was reduced by 4.67% with the 10,750-share transaction.

The shares most recently traded at $42.57, up $0.55, or 1.3% since the insider transaction. Historical insider transactions for Enanta Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 24,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 32,000
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 81,500

The average volume for Enanta Pharmaceuticals has been 315,500 shares per day over the past 30 days. Enanta Pharmaceuticals has a market cap of $787.5 million and is part of the health care sector and drugs industry. Shares are down 16.68% year-to-date as of the close of trading on Monday.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. The company has a P/E ratio of 7.0. Currently, there are 3 analysts who rate Enanta Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENTA - FREE

TheStreet Quant Ratings rates Enanta Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Enanta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Strong On High Relative Volume: Enanta Pharmaceuticals (ENTA)

Insider Trading Alert - ENTA, EBIO And PSEC Traded By Insiders

5 Hated Stocks You Should Love

Insider Trading Alert - ENTA, HBI And MOFG Traded By Insiders

Enanta Pharmaceuticals (ENTA) Showing Signs Of Perilous Reversal Today